DISEASE INDICATIONS: Gynaecological Cancer

MANUFACTURER: Tesaro UK Limited

USAGE: Oral

MEDICINE APPROVED BY:

European Medical Agency (EMA)

Food and Drug Administration (FDA)

Health Canada

Therapeutic Goods Administration (TGA)

Zejula is an oral PARP inhibitor used for the treatment of recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancers in adult patients. Its mechanism of action blocks the PARP enzyme, preventing cancer cells from repairing damaged DNA causing their death.